Board of Directors
Mr. Lefkoff has served as Chairman of the Board of Directors from May 1998 to January 2012, and was again appointed Chairman in April 2012 and still serves in that role. From January to April 2012, Mr. Lefkoff served as Executive Chairman on an interim basis pending appointment of a new Chief Executive Officer for Array. Since 1995, Mr. Lefkoff has been a General Partner of Boulder Ventures Limited, a venture capital firm and a prior investor in Array. In his thirty-year career as a venture capitalist, Mr. Lefkoff has invested in 57 Colorado companies, resulting in fourteen Initial Public Offerings and fifteen trade sales. From 1986 until 1995, Mr. Lefkoff was employed by Colorado Venture Management, a venture capital firm. Mr. Lefkoff serves on the Board of Directors for miRagen Therapeutics, MarketForce Information, Black Bear Energy and CommercialTribe. Mr. Lefkoff received a B.A. in economics from Vassar College and an M.B.A. in finance from the University of Chicago.
As part of his responsibilities as an Array Board member, Mr. Lefkoff serves on Array's Audit and Compensation committees.
Dr. Baum has served as a member of our Board of Directors since April 2014. Dr. Baum has served as the President and Chief Executive Officer of Mirati since 2012. Previously, he was the Senior Vice President for Clinical Research within Pfizer's Worldwide Research & Development division. Dr. Baum had worked at Pfizer from 2003 until he joined Mirati in 2012, taking on roles of increasing responsibility, including Vice President and Head of Oncology Development and Chief Medical Officer for Pfizer's Biotherapeutics and Bioinnovation Center, a Pfizer division comprised of small biotech research units. During his tenure at Pfizer he was responsible for the development of the company’s oncology portfolio, including the tyrosine kinase inhibitors Sutent® (sunitinib), Inlyta® (axitinib) and Xalkori® (crizotinib). Prior to joining Pfizer, Dr. Baum was responsible for the Phase I-IV development of several oncology compounds at Schering-Plough, including Temodar® (temozolomide). Dr. Baum received his M.D. and Ph.D. (Immunology) degrees from the Washington University School of Medicine and did his post-graduate work at Stanford University, where he completed his medical training and conducted research on human bone marrow stem cells with Dr. Irving Weissman. Dr. Baum was granted research support by the National Institutes of Health and the American Cancer Society, published more than 50 peer-reviewed manuscripts, and holds a number of patents and patent applications.
As part of his responsibilities as an Array Board member, Dr. Baum serves on Array's Audit and Clinical Development Committees.
Independent Consultant & Former Vice President, Oncology Development, Genentech, Inc.
Dr. Fyfe has served as a member of our Board of Directors since January 2012. From 1997 to 2009, Dr. Fyfe held various positions with Genentech, Inc. (now a member of the Roche Group), including Vice President, Oncology Development; Vice President, Avastin® Franchise Team; as well as the honorary title of Senior Staff Scientist. Dr. Fyfe played an important role in the development of Genentech’s approved oncology agents including Rituxan®, Herceptin®, Avastin® and Tarceva®. Dr. Fyfe sat on the development oversight committee for all of Genentech’s products and participated in the Research Review Committee that moved products from research into clinical development. Since leaving Genentech in 2009, Dr. Fyfe has been a consultant for venture capital firms and for a variety of biotechnology companies. Dr. Fyfe is a recognized oncology expert in the broader oncology community and has been an invited member of Institute of Medicine panels, National Cancer Institute working groups and grant committees and American Society of Clinical Oncologists oversight committees. She is a graduate of Washington University School of Medicine and a board certified pediatric oncologist.
As part of her responsibilities as an Array Board member, Dr. Fyfe serves on Array's Compensation, Corporate Governance and Clinical Development Committees.
Mr. Orwin has served as a member of our Board of Directors since November 2012. Mr. Orwin has served as the chief executive officer of Relypsa since May 2013. Previously he was the chief executive officer at Affymax since 2011, after joining the company in 2010 as its chief operating officer. He held leadership roles in marketing, sales, and operations for major pharmaceutical companies including Genentech, Johnson & Johnson, Alza Pharmaceuticals, Rhone-Poulenc Rorer, and Schering-Plough Corporation. Mr. Orwin brings a track record of substantial accomplishment in the pharmaceutical industry to Array’s board of directors. Over his career, Mr. Orwin has built successful businesses and commercialized a range of blockbuster products. Most recently, he led the approval and launch of Omontys®, a hematology product for the treatment of anemia in chronic kidney disease. Prior to joining Affymax, he led Genentech’s BioOncology business unit and grew a portfolio of cancer-fighting products including Avastin®, Rituxan®, Herceptin® and Tarceva® to over $7 billion in U.S. sales. Earlier in his career, he was responsible for the successful launch of Taxotere®, exceeding budget and forecast expectations. Mr. Orwin is currently chairman of the board of Affymax and a member of the board of directors of Relypsa.
As part of his responsibilities as an Array Board member, Mr. Orwin serves on Array's Compensation, Corporate Governance and Clinical Development Committees.
Mr. Van Lunsen has served as a member of our Board of Directors since October 2002. Prior to his retirement in June 2000, Mr. Van Lunsen was a Managing Partner of KPMG LLP and led the firm’s Tulsa, Oklahoma office. During his 33-year career, Mr. Van Lunsen held various positions of increasing responsibility with KPMG and was elected to the partnership in 1977. Mr. Van Lunsen is currently Chairman of both the Audit Committee and the Conflicts Committee at ONEOK Partners, GP, L.L.C. in Tulsa, Oklahoma. Additionally, Mr. Van Lunsen is the Audit Committee Chairman and a member of the Governance Committee and Compensation Committee at M/A-Com Technology Solutions, Inc. in Lowell, Massachusetts. Mr. Van Lunsen received a B.S./B.A. in Accounting from the University of Denver.
As part of his responsibilities as an Array Board member, Mr. Van Lunsen serves on Array's Audit and Corporate Governance Committees.
Ron Squarer has served as Chief Executive Officer and a member of the Array Board of Directors since April 2012. Mr. Squarer has extensive commercial, development and executive leadership expertise from a 20 year career in the pharmaceutical industry. Most recently he served as Chief Commercial Officer at Hospira Inc., a global pharmaceutical and medical device company, where he was responsible for delivering $4 billion in annual revenue and leading more than 2,000 employees worldwide. Prior to this, Mr. Squarer was responsible for strategy, new product development and commercialization, acquisitions, partnerships and portfolio prioritization as Senior Vice President, Global Marketing and Corporate Development. Mr. Squarer joined Hospira from Mayne Pharma, an oncology-focused, global pharmaceutical company, where he served as Senior Vice President, Global Corporate and Business Development when Mayne was sold to Hospira for $2 billion in 2007. Earlier, Mr. Squarer held senior management roles at both Pfizer, Inc., focused on global oncology commercial development, and at SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline) in the U.S. and Europe. Mr. Squarer holds an MBA from the Kellogg School of Management, Northwestern University and a bachelor’s degree in biochemistry from the University of California, Berkeley.